CY2012003I1 - Αντισωματα που συνδεονται ανοσοειδικως προς blys - Google Patents

Αντισωματα που συνδεονται ανοσοειδικως προς blys

Info

Publication number: CY2012003I1
Authority: CY; Cyprus
Prior art keywords: blys; antibodies; bind immunospecifically; immunospecifically; bind
Prior art date: 2000-06-16

Application number

CY2012003C

Other languages

English (en)

Other versions

CY2012003I2 (el

Original Assignee

Human Genome Sciences, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-16

Filing date

2012-01-10

Publication date

2016-12-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27539647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2012003(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-01-10 Application filed by Human Genome Sciences, Inc. filed Critical Human Genome Sciences, Inc.

2016-12-14 Publication of CY2012003I1 publication Critical patent/CY2012003I1/el

2020-05-29 Publication of CY2012003I2 publication Critical patent/CY2012003I2/el

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Rheumatology (AREA)
Zoology (AREA)
Pathology (AREA)
Epidemiology (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Rehabilitation Therapy (AREA)

CY2012003C 2000-06-16 2012-01-10 Αντισωματα που συνδεονται ανοσοειδικως προς blys CY2012003I2 (el)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US21221000P	2000-06-16	2000-06-16
US24081600P	2000-10-17	2000-10-17
US27624801P	2001-03-16	2001-03-16
US27737901P	2001-03-21	2001-03-21
US29349901P	2001-05-25	2001-05-25
PCT/US2001/019110 WO2002002641A1 (en)	2000-06-16	2001-06-15	Antibodies that immunospecifically bind to blys

Publications (2)

Publication Number	Publication Date
CY2012003I1 true CY2012003I1 (el)	2016-12-14
CY2012003I2 CY2012003I2 (el)	2020-05-29

Family

ID=27539647

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
CY20111100348T CY1112793T1 (el)	2000-06-16	2011-04-04	Αντισωματα που συνδεονται ανοσοειδικως προς blys
CY2012003C CY2012003I2 (el)	2000-06-16	2012-01-10	Αντισωματα που συνδεονται ανοσοειδικως προς blys
CY20161101283T CY1118317T1 (el)	2000-06-16	2016-12-13	Αντισωματα που ανοσοειδικως συνδεονται προς blys
CY20161101319T CY1118363T1 (el)	2000-06-16	2016-12-19	Αντισωματα που ανοσοειδικως συνδεονται προς blys

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CY20111100348T CY1112793T1 (el)	2000-06-16	2011-04-04	Αντισωματα που συνδεονται ανοσοειδικως προς blys

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
CY20161101283T CY1118317T1 (el)	2000-06-16	2016-12-13	Αντισωματα που ανοσοειδικως συνδεονται προς blys
CY20161101319T CY1118363T1 (el)	2000-06-16	2016-12-19	Αντισωματα που ανοσοειδικως συνδεονται προς blys

Country Status (20)

Country	Link
US (4)	US7138501B2 (el)
EP (4)	EP2275449B1 (el)
JP (2)	JP4902087B2 (el)
KR (4)	KR20120053525A (el)
CN (1)	CN1279055C (el)
AT (1)	ATE494304T1 (el)
AU (3)	AU6842701A (el)
BE (1)	BE2012C005I2 (el)
CA (1)	CA2407910C (el)
CY (4)	CY1112793T1 (el)
DE (1)	DE60143798D1 (el)
DK (1)	DK1294769T3 (el)
ES (3)	ES2609583T3 (el)
FR (1)	FR12C0001I2 (el)
HK (1)	HK1051697A1 (el)
LU (1)	LU91926I2 (el)
MX (1)	MXPA02012434A (el)
NZ (1)	NZ522700A (el)
PT (2)	PT2275449T (el)
WO (1)	WO2002002641A1 (el)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8212004B2 (en) *	1999-03-02	2012-07-03	Human Genome Sciences, Inc.	Neutrokine-alpha fusion proteins
US6812327B1 (en) *	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
US7244826B1 (en) *	1998-04-24	2007-07-17	The Regents Of The University Of California	Internalizing ERB2 antibodies
AU762839B2 (en)	1999-01-25	2003-07-03	Apoxis Sa	Baff, related blocking agents and their use in the stimulation and inhibition of B-cells and immunoglobulins in immune responses
US20030095967A1 (en)	1999-01-25	2003-05-22	Mackay Fabienne	BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
DK2204186T3 (en)	1999-02-17	2016-07-18	Csl Ltd	Immunogenic complexes, and related methods
BR0013391A (pt)	1999-08-17	2002-07-09	Biogen Inc	Uso do receptor baff (bcma) como um agente imunoregulador
UA74798C2 (uk)	1999-10-06	2006-02-15	Байоджен Айдек Ма Інк.	Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
US7879328B2 (en) *	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
US7220840B2 (en) *	2000-06-16	2007-05-22	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator protein
WO2002002641A1 (en) *	2000-06-16	2002-01-10	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to blys
JP2004532604A (ja) *	2000-08-18	2004-10-28	ダイアックスコーポレーション	Ｂリンパ球刺激因子タンパク質（ＢＬｙＳ）のための結合性ポリペプチド
AU2001288301A1 (en) *	2000-08-18	2002-03-04	Human Genome Sciences, Inc.	Binding polypeptides and methods based thereon
UA83458C2 (uk)	2000-09-18	2008-07-25	Байоджен Айдек Ма Інк.	Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
GB0024200D0 (en) *	2000-10-03	2000-11-15	Smithkline Beecham Sa	Component vaccine
CA2426710A1 (en) *	2000-11-08	2002-10-10	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to trail receptors
AU2002249854B2 (en)	2000-12-18	2007-09-20	Dyax Corp.	Focused libraries of genetic packages
ES2376454T3 (es) *	2000-12-22	2012-03-14	Grad, Carole, Legal Representative Of Howard, Kaplan	Librer�?as de expresión en fago de fragmentos vh humanos.
US7189820B2 (en) *	2001-05-24	2007-03-13	Human Genome Sciences, Inc.	Antibodies against tumor necrosis factor delta (APRIL)
US7348003B2 (en)	2001-05-25	2008-03-25	Human Genome Sciences, Inc.	Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en)	2001-05-25	2008-04-22	Human Genome Sciences, Inc.	Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
DK1572874T3 (da) *	2001-05-25	2013-12-16	Human Genome Sciences Inc	Antistoffer, der immunospecifikt binder til TRAIL receptorer
JP2004538324A (ja)	2001-08-03	2004-12-24	メディカルリサーチカウンシル	細胞内抗体
AR035119A1 (es)	2001-08-16	2004-04-14	Lilly Co Eli	Anticuerpos humanos antagonistas anti-htnfsf13b
US7112410B1 (en) *	2001-08-29	2006-09-26	Human Genome Sciences, Inc.	Human tumor necrosis factor TR21 and methods based thereon
US7658924B2 (en) *	2001-10-11	2010-02-09	Amgen Inc.	Angiopoietin-2 specific binding agents
US7521053B2 (en) *	2001-10-11	2009-04-21	Amgen Inc.	Angiopoietin-2 specific binding agents
WO2003040172A2 (en) *	2001-11-09	2003-05-15	Aegera Therapeutics, Inc.	Methods and reagents for peptide-bir interaction screens
AU2002364954A1 (en) *	2001-11-16	2003-07-15	Human Genome Sciences, Inc.	ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
JP5153990B2 (ja) *	2001-12-21	2013-02-27	シーエスエル、リミテッド	免疫反応性試薬およびサポニンを含有する組成物、およびその使用方法
CN1652821A (zh) *	2002-01-28	2005-08-10	米德列斯公司	抗前列腺特异性膜抗原(psma)的人单克隆抗体
WO2003089575A2 (en) *	2002-04-15	2003-10-30	Human Genome Sciences, Inc.	Antibodies that specifically bind to tl5
EP1551453A4 (en) *	2002-06-17	2007-04-25	Us Gov Health & Human Serv	SPECIFICITY GRAFTING OF A MICE RESPONSE TO A HUMAN FRAME
US7601351B1 (en)	2002-06-26	2009-10-13	Human Genome Sciences, Inc.	Antibodies against protective antigen
WO2004003144A2 (en) *	2002-07-01	2004-01-08	Human Genome Sciences, Inc.	Antibodies that specifically bind to reg iv
AU2003249533A1 (en)	2002-07-04	2004-01-23	Oncomab Gmbh	Neoplasm specific antibodies and uses thereof
WO2004013287A2 (en) *	2002-08-02	2004-02-12	Human Genome Sciences, Inc.	Antibodies against c3a receptor
WO2004044556A2 (en) *	2002-11-12	2004-05-27	Becton, Dickinson And Company	Diagnosis of sepsis or sirs using biomarker profiles
KR20050106459A (ko)	2003-02-28	2005-11-09	미쯔비시 웰 파마 가부시키가이샤	단일클론 항체, 이를 코딩하는 유전자, 하이브리도마, 의약조성물 및 진단 시약
EP1603949B9 (en)	2003-03-14	2011-02-02	Wyeth LLC	Antibodies against human il-21 receptor and uses therefor
DE10311248A1 (de) *	2003-03-14	2004-09-30	Müller-Hermelink, Hans Konrad, Prof. Dr.	Humaner monoklonaler Antikörper
JP5524441B2 (ja)	2003-03-28	2014-06-18	バイオジェン・アイデック・エムエイ・インコーポレイテッド	短縮されたｂａｆｆレセプター
WO2004097019A1 (ja) *	2003-04-30	2004-11-11	Japan Science And Technology Agency	ヒト抗ヒトインターロイキン－１８抗体およびその断片、並びにそれらの利用方法
CA2526402A1 (en)	2003-06-05	2005-01-20	Genentech, Inc.	Blys antagonists and uses thereof
CN102675462A (zh)	2003-06-27	2012-09-19	艾默根佛蒙特有限公司	针对表皮生长因子受体的缺失突变体的抗体及其使用
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
DE10353175A1 (de)	2003-11-14	2005-06-16	Müller-Hermelink, Hans Konrad, Prof. Dr.	Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (en)	2003-11-14	2005-05-18	Heinz Vollmers	Adenocarcinoma specific antibody SAM-6, and uses thereof
CA2545893A1 (en) *	2003-11-14	2005-06-02	Massachusetts Institute Of Technology	Anti-hydroxylase antibodies and uses thereof
US20070249530A1 (en) *	2004-01-29	2007-10-25	Genentech, Inc.	Bcma Polypeptides and Uses Thereof
US20080050391A1 (en) *	2004-03-30	2008-02-28	Lazarus Alan H	Method for Treating Autoimmune Diseases With Antibodies
KR100923828B1 (ko) *	2004-03-31	2009-10-27	캐논 가부시끼가이샤	금-결합성 단백질
US7763249B2 (en) *	2004-04-27	2010-07-27	Juridical Foundation The Chemo-Sero-Therapeutic Research Institute	Human anti-amyloid β peptide antibody and fragment of said antibody
WO2005108986A1 (en) *	2004-05-10	2005-11-17	Korea Research Institute Of Bioscience And Biotechnology	A diagnostic method of asthma using baff as a diagnostic marker
GB0417487D0 (en)	2004-08-05	2004-09-08	Novartis Ag	Organic compound
US20080050381A1 (en) *	2004-08-31	2008-02-28	Tsutomu Takeuchi	Antihuman Baff Antibody
US20060246075A1 (en) *	2004-09-29	2006-11-02	Marc Mercken	Anti-amyloid antibodies, compositions, methods and uses
WO2006081516A2 (en) *	2005-01-28	2006-08-03	Biogen Idec Ma Inc.	USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS
US20070009972A1 (en) *	2005-02-16	2007-01-11	Ginger Chao	Epidermal growth factor receptor polypeptides and antibodies
AU2011247831B8 (en) *	2005-03-25	2014-02-20	National Research Council Of Canada	Method for isolation of soluble polypeptides
EP2351842A1 (en) *	2005-03-25	2011-08-03	National Research Council Of Canada	Method for isolation of soluble polypeptides
AU2006236588A1 (en)	2005-04-15	2006-10-26	Becton, Dickinson And Company	Diagnosis of sepsis
US20060240006A1 (en) *	2005-04-20	2006-10-26	Chishih Chu	Novel antibody structures derived from human germline sequences
NZ597082A (en) *	2005-10-13	2013-11-29	Human Genome Sciences Inc	Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
US9168286B2 (en) *	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
JP4736037B2 (ja) *	2005-10-26	2011-07-27	株式会社イーベック	ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
WO2007062090A2 (en) *	2005-11-23	2007-05-31	Genentech, Inc.	Methods and compositions related to b cell assays
WO2007085814A1 (en) *	2006-01-24	2007-08-02	Domantis Limited	Fusion proteins that contain natural junctions
TW200745163A (en)	2006-02-17	2007-12-16	Syntonix Pharmaceuticals Inc	Peptides that block the binding of IgG to FcRn
US8211649B2 (en)	2006-03-31	2012-07-03	Human Genome Sciences, Inc.	Methods of diagnosing and prognosing hodgkin's lymphoma
JP2007306828A (ja) *	2006-05-17	2007-11-29	Tokai Univ	非還元マンノース残基を認識するファージ提示型単鎖抗体
US7981417B2 (en) *	2006-06-07	2011-07-19	Wisconsin Alumni Research Foundation	Blood-brain barrier targeting anti-bodies
JP2009540799A (ja) *	2006-06-07	2009-11-26	ウイスコンシンアラムナイリサーチフオンデーシヨン	血液脳関門標的化抗体
EP2975057A1 (en) *	2006-07-10	2016-01-20	Fujita Health University	Novel anti-cd73 antibody
PE20080980A1 (es)	2006-10-12	2008-09-02	Genentech Inc	Anticuerpos anti-linfotoxina alfa
WO2008140483A2 (en) *	2006-11-09	2008-11-20	Human Genome Sciences, Inc.	Methods and antibodies for detecting protective antigen
EP2104682B1 (en) *	2007-01-11	2016-09-21	Michael Bacher	Diagnosis and treatment of alzheimer's and other neurodementing diseases
US20100166772A1 (en) *	2007-05-31	2010-07-01	Anderson Annaliesa S	ANTIGEN-BINDING PROTEINS TARGETING S. AUREUS ORF0657n
CL2008002153A1 (es) *	2007-07-24	2009-06-05	Amgen Inc	Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
EP2185719B1 (en) *	2007-08-02	2013-11-13	NovImmune SA	Anti-rantes antibodies and methods of use thereof
WO2009020867A2 (en)	2007-08-09	2009-02-12	Syntonix Pharmaceuticals, Inc.	Immunomodulatory peptides
AR068767A1 (es) *	2007-10-12	2009-12-02	Novartis Ag	Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
WO2009052293A1 (en)	2007-10-16	2009-04-23	Zymogenetics, Inc.	Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
UY31466A1 (es) *	2007-11-13	2009-07-17		Anticuerpos monoclonales que se unen al hgm-csf y las composiciones médicas que los comprenden
JO2913B1 (en)	2008-02-20	2015-09-15	امجين إنك,	Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2009123737A2 (en)	2008-04-03	2009-10-08	Becton, Dickinson And Company	Advanced detection of sepsis
HRP20240722T1 (hr)	2008-04-11	2024-08-30	Chugai Seiyaku Kabushiki Kaisha	Molekula koja se veže na antigene, koja se može ponavljano vezati na dvje ili više molekula antigena
EP2268668A1 (en) *	2008-04-17	2011-01-05	Ablynx N.V.	Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
EP2283355A2 (en)	2008-04-25	2011-02-16	Zymogenetics, Inc.	Levels of bcma protein expression on b cells and use in diagnostic methods
US8003335B2 (en)	2008-04-30	2011-08-23	Universite Paris-SUD11	Levels of APRIL in serum and use in diagnostic methods
PT2291657T (pt)	2008-05-01	2016-07-08	Zymogenetics Inc	Níveis séricos de heterotrímeros blys/april e utilização em métodos de diagnóstico
WO2010004438A2 (en) *	2008-06-16	2010-01-14	Patrys Limited	Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
UA112050C2 (uk) *	2008-08-04	2016-07-25	БАЄР ХЕЛСКЕР ЛЛСі	Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
AR072999A1 (es) *	2008-08-11	2010-10-06	Medarex Inc	Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
JP2012502649A (ja) *	2008-09-19	2012-02-02	メディミューン，エルエルシー	Ｃｄ１０５を対象とする標的結合剤およびその使用
TWI440469B (zh)	2008-09-26	2014-06-11	Chugai Pharmaceutical Co Ltd	Improved antibody molecules
EP2376120A2 (en) *	2008-11-25	2011-10-19	Biogen Idec MA Inc.	Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
EP2396035A4 (en) *	2009-02-12	2012-09-12	Human Genome Sciences Inc	USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
AU2010236256C1 (en) *	2009-04-16	2015-10-22	Abbvie Biotherapeutics Inc.	Anti-TNF-alpha antibodies and their uses
WO2010141249A2 (en) *	2009-06-02	2010-12-09	Merck Sharp & Dohme Corp.	Generation, characterization and uses thereof of anti-notch3 antibodies
US8728730B2 (en)	2009-09-03	2014-05-20	Genentech, Inc.	Methods for treating, diagnosing, and monitoring rheumatoid arthritis
MY174760A (en)	2010-03-01	2020-05-13	Bayer Healthcare Llc	Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2011109280A1 (en)	2010-03-05	2011-09-09	Lerner Research Institute	Methods and compositions to treat immune-mediated disorders
WO2011139375A1 (en) *	2010-05-06	2011-11-10	Ludwig Institute For Cancer Research Ltd	Antibodies directed against carbonic anhydrase ix and methods and uses thereof
EP2582392A4 (en) *	2010-06-18	2015-02-18	Human Genome Sciences Inc	USE OF ANTAGONISTS OF A LYMPHOCYTE B STIMULATING PROTEIN FOR THE TREATMENT OF ASTHMA AND OTHER ALLERGIC AND INFLAMMATORY DISEASES OF THE RESPIRATORY SYSTEM
RU2598711C2 (ru)	2010-07-22	2016-09-27	Те Риджентс Оф Те Юниверсити Оф Калифорния	Антитело к противоопухолевому антигену и способы применения
US8871737B2 (en)	2010-09-22	2014-10-28	Alios Biopharma, Inc.	Substituted nucleotide analogs
EP3050899B1 (en)	2010-09-27	2019-09-04	Janssen Biotech, Inc.	Antibodies binding human collagen ii
US8906649B2 (en)	2010-09-27	2014-12-09	Janssen Biotech, Inc.	Antibodies binding human collagen II
RU2658504C9 (ru)	2010-11-30	2018-08-21	Чугаи Сейяку Кабусики Кайся	Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
CN103442768A (zh) *	2011-01-18	2013-12-11	宾夕法尼亚大学董事会	治疗癌的组合物和方法
SG192945A1 (en)	2011-02-25	2013-09-30	Chugai Pharmaceutical Co Ltd	Fcgriib-specific fc antibody
RU2013140975A (ru)	2011-02-28	2015-04-10	Дженентек, Инк.	Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток
DE102011006809A1 (de)	2011-04-05	2012-10-11	Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg	Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
RU2660370C2 (ru) *	2011-07-22	2018-07-05	Цсл Беринг Гмбх	Ингибирующие моноклональные антитела против фактора xii/xiia и их применения
WO2013022968A1 (en) *	2011-08-09	2013-02-14	Athera Biotechnologies Ab	Antibodies binding to phosphorylcholine (pc) and/or pc conjugates
TW201817745A (zh)	2011-09-30	2018-05-16	日商中外製藥股份有限公司	具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP3939996A1 (en)	2011-09-30	2022-01-19	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CA2860234A1 (en)	2011-12-22	2013-06-27	Alios Biopharma, Inc.	Substituted phosphorothioate nucleotide analogs
US8962315B2 (en)	2011-12-22	2015-02-24	Elwha Llc	Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
US9175072B2 (en)	2011-12-22	2015-11-03	Elwha Llc	Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
US10745468B2 (en)	2011-12-22	2020-08-18	Kota Biotherapeutics, Llc	Compositions and methods for modified B cells expressing reassigned biological agents
US10233424B2 (en)	2011-12-22	2019-03-19	Elwha Llc	Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
WO2013106572A1 (en) *	2012-01-11	2013-07-18	Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University	Bispecific antibody fragments for neurological disease proteins and methods of use
WO2013142124A1 (en)	2012-03-21	2013-09-26	Vertex Pharmaceuticals Incorporated	Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142157A1 (en)	2012-03-22	2013-09-26	Alios Biopharma, Inc.	Pharmaceutical combinations comprising a thionucleotide analog
US9107904B2 (en) *	2012-04-05	2015-08-18	Massachusetts Institute Of Technology	Immunostimulatory compositions and methods of use thereof
CN103421113B (zh) *	2012-05-22	2018-01-19	武汉华鑫康源生物医药有限公司	抗BLyS抗体
CN104603151A (zh)	2012-05-31	2015-05-06	索伦托治疗有限公司	与dll-4结合的抗原结合蛋白
AR091649A1 (es)	2012-07-02	2015-02-18	Bristol Myers Squibb Co	Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN104662044B (zh)	2012-08-24	2018-10-30	加利福尼亚大学董事会	用于治疗ror1癌症并抑制转移的抗体和疫苗
RS57807B1 (sr) *	2012-09-12	2018-12-31	Neurimmune Holding Ag	Antitela specifična za amiloidni polipeptid humanih ostrvaca (hiapp) i njihova upotreba
US9458246B2 (en)	2013-03-13	2016-10-04	Amgen Inc.	Proteins specific for BAFF and B7RP1
CN104045713B (zh) *	2013-03-13	2019-02-12	江苏诺迈博生物医药科技有限公司	一种抗Blys的单克隆抗体及含有该抗体的药物组合物
PH12022550138A1 (en) *	2013-03-13	2023-03-06	Amgen Inc	Proteins specific for baff and b7rp1 and uses thereof
BR112015021399A2 (pt)	2013-03-14	2017-07-18	Bayer Healthcare Llc	anticórpos monoclonais contra antitrombina beta complexada com heparina
SMT201900332T1 (it)	2013-09-20	2019-07-11	Bristol Myers Squibb Co	Combinazione di anticorpi anti-lag-3 e anticorpi anti-pd-1 per il trattamento di tumori
BR112016014072B1 (pt)	2013-12-17	2023-12-26	Kling Biotherapeutics B.V.	Anticorpo isolado, sintético ou recombinante humano, ou uma parte funciona do mesmo, molécula de ácido nucleico isolado, vetor, composição, uso de um anticorpo ou parte funcional, ou uma molécula de ácido nucleico ou um vetor e, métodos para produzir um anticorpo ou parte funcional, e para determinar se céuluas aml ou células de linfoma ou células de mieloma múltiplo ou células b de linfoma não hodgkin estão presentes em uma amostra
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN104804091B (zh) *	2014-01-29	2018-03-27	普瑞金（深圳）生物技术有限公司	一种抗b细胞生长刺激因子的纳米抗体及用途
CN104804092B (zh) *	2014-01-29	2018-03-27	天津胜发生物技术有限公司	一种抗b细胞生长刺激因子的纳米抗体及其用途
CN104804090B (zh) *	2014-01-29	2018-03-27	普瑞金（深圳）生物技术有限公司	一种抗b细胞生长刺激因子的纳米抗体和用途
EA033604B1 (ru)	2014-01-31	2019-11-08	Boehringer Ingelheim Int	Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
ME03558B (me)	2014-03-14	2020-07-20	Novartis Ag	Molekuli anti-lag-3 antiтela i njihove upotrebe
US10434174B2 (en)	2014-06-09	2019-10-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
US10758614B2 (en)	2014-06-09	2020-09-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health	Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
WO2015191568A2 (en) *	2014-06-09	2015-12-17	Biomed Valley Discoveries, Inc.	Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
US10758526B2 (en)	2014-06-09	2020-09-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health	Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
WO2015191615A2 (en) *	2014-06-09	2015-12-17	Biomed Valley Discoveries, Inc.	Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents
US11033621B2 (en)	2014-06-09	2021-06-15	Biomed Valley Discoveries, Inc.	Combination therapies targeting tumor-associated stroma or tumor cells
US10758613B2 (en)	2014-06-09	2020-09-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Intstitutes Of Health	Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
US11033620B2 (en)	2014-06-09	2021-06-15	Biomed Valley Discoveries, Inc.	Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
US9683017B2 (en)	2014-07-17	2017-06-20	University Tennessee Research Foundation	Inhibitory peptides of viral infection
EP3186273A4 (en)	2014-08-26	2018-05-02	University of Tennessee Research Foundation	Targeting immunotherapy for amyloidosis
CA3005158A1 (en)	2014-11-06	2016-05-12	Scholar Rock, Inc.	Anti-pro/latent-myostatin antibodies and uses thereof
EP3227436B1 (en)	2014-12-05	2024-11-13	Memorial Sloan Kettering Cancer Center	Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
SI3227339T1 (sl)	2014-12-05	2022-02-28	Memorial Sloan-Kettering Cancer Center	Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba
CA2969877A1 (en)	2014-12-05	2016-06-09	Memorial Sloan-Kettering Cancer Center	Antibodies targeting b-cell maturation antigen and methods of use
NZ732563A (en)	2014-12-05	2023-01-27	Memorial Sloan Kettering Cancer Center	Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
PE20171111A1 (es)	2014-12-19	2017-08-07	Chugai Pharmaceutical Co Ltd	Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso
EA201791366A1 (ru)	2014-12-19	2018-02-28	Чугаи Сейяку Кабусики Кайся	Антитела к c5 и способы их применения
AR103442A1 (es)	2015-01-16	2017-05-10	Juno Therapeutics Inc	Anticuerpos y receptores de antígenos quiméricos específicos de ror1
JP2018510842A (ja)	2015-02-05	2018-04-19	中外製薬株式会社	イオン濃度依存的抗原結合ドメインを含む抗体、Ｆｃ領域改変体、ＩＬ−８に結合する抗体、およびその使用
CN114014930A (zh) *	2015-02-13	2022-02-08	索伦托药业有限公司	结合ctla4的抗体治疗剂
TWI759261B (zh)	2015-02-27	2022-04-01	日商中外製藥股份有限公司	Ｉｌ－６受體抗體用於製備醫藥組成物的用途
AR104368A1 (es)	2015-04-03	2017-07-19	Lilly Co Eli	Anticuerpos biespecíficos anti-cd20- / anti-baff
WO2016164530A1 (en) *	2015-04-07	2016-10-13	University Of Maryland, College Park	Compositions and methods for high throughput protein sequencing
US9951144B2 (en)	2015-04-08	2018-04-24	Sorrento Therapeutics, Inc.	Antibody therapeutics that bind CD38
WO2016205042A1 (en) *	2015-06-16	2016-12-22	The Board Of Trustees Of The Leland Stanford Junior University	SIRPα AGONIST ANTIBODY
TWI733685B (zh)	2015-07-23	2021-07-21	德商包林格因蓋爾漢國際股份有限公司	靶向il-23a與b細胞活化因子(baff)之化合物及其用途
PE20181322A1 (es) *	2015-09-01	2018-08-14	Agenus Inc	Anticuerpo anti-pd1 y sus metodos de uso
EP4461312A3 (en)	2015-09-15	2025-01-22	Scholar Rock, Inc.	Anti-pro/latent-myostatin antibodies and uses thereof
CN109071654B (zh) *	2015-12-04	2022-09-23	纪念斯隆-凯特琳癌症中心	靶向Fc受体样5的抗体及使用方法
EP3394098A4 (en)	2015-12-25	2019-11-13	Chugai Seiyaku Kabushiki Kaisha	ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
EP3400240A2 (en)	2016-01-08	2018-11-14	Scholar Rock, Inc.	Anti-pro/latent myostatin antibodies and methods of use thereof
AU2017213844A1 (en)	2016-02-02	2018-08-02	Fred Hutchinson Cancer Center	Anti-ROR1 antibodies and uses thereof
KR20180107111A (ko)	2016-02-17	2018-10-01	시애틀 지네틱스, 인크.	암 및 면역학적 장애를 치료하기 위한 bcma 항체 및 이의 용도
WO2017184973A1 (en) *	2016-04-22	2017-10-26	University Of Tennessee Research Foundation	Identifying amyloidogenic proteins & amyloidogenic risk
PT3368069T (pt)	2016-06-13	2020-11-11	Scholar Rock Inc	Uso de inibidores da miostatina e terapias de combinação
IL299099B1 (en)	2016-06-27	2025-03-01	Univ California	Combinations of cancer treatments
EP3484499A4 (en) *	2016-07-14	2020-05-13	Scholar Rock, Inc.	TGFB ANTIBODIES, METHODS AND USE
WO2018013924A1 (en)	2016-07-15	2018-01-18	Massachusetts Institute Of Technology	Synthetic nanoparticles for delivery of immunomodulatory compounds
CN109689099B (zh)	2016-08-05	2023-02-28	中外制药株式会社	用于预防或治疗il-8相关疾病的组合物
WO2018039107A1 (en) *	2016-08-22	2018-03-01	Medimmune, Llc	Binding molecules specific for notch4 and uses thereof
WO2018035710A1 (en) *	2016-08-23	2018-03-01	Akeso Biopharma, Inc.	Anti-ctla4 antibodies
PE20190921A1 (es)	2016-12-07	2019-06-26	Agenus Inc	Anticuerpos y metodos de su utilizacion
EP3565592B1 (en)	2017-01-06	2023-03-01	Scholar Rock, Inc.	Treating metabolic diseases by inhibiting myostatin activation
WO2018139623A1 (en)	2017-01-30	2018-08-02	Chugai Seiyaku Kabushiki Kaisha	Anti-sclerostin antibodies and methods of use
EP3582782B1 (en)	2017-02-17	2023-06-07	Fred Hutchinson Cancer Center	Combination therapies for treatment of bcma-related cancers and autoimmune disorders
JP7185884B2 (ja)	2017-05-02	2022-12-08	国立研究開発法人国立精神・神経医療研究センター	Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
AU2018277824A1 (en)	2017-05-30	2019-10-17	Bristol-Myers Squibb Company	Treatment of LAG-3 positive tumors
WO2018222722A2 (en)	2017-05-30	2018-12-06	Bristol-Myers Squibb Company	Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
AU2018352245A1 (en)	2017-10-16	2020-04-30	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-CD22 immunotherapy
JP7256197B2 (ja)	2017-11-01	2023-04-11	ジュノーセラピューティクスインコーポレイテッド	Ｂ細胞成熟抗原に特異的な抗体およびキメラ抗原受容体
PT3703750T (pt)	2017-11-01	2025-01-17	Memorial Sloan Kettering Cancer Center	Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
MA50564A (fr)	2017-11-06	2020-09-16	Hutchinson Fred Cancer Res	Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase
JP2021516991A (ja)	2018-03-02	2021-07-15	エリシオセラピューティクス，インク．ＥｌｉｃｉｏＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	Ｃｐｇアンフィフィル及びその使用
US20210301020A1 (en) *	2018-07-24	2021-09-30	Amgen Inc.	Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
EP3883610A4 (en)	2018-11-20	2022-11-02	Cornell University	MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN CANCER RADIATION THERAPY
CN113574071B (zh)	2019-03-15	2025-03-25	莫佛塞斯公司	用于治疗自身抗体介导的自身免疫疾病的抗-cd38抗体及其药物组合物
IL297143A (en) *	2020-04-08	2022-12-01	Janssen Biotech Inc	Anti-cd98 antibodies and their uses
US20230212266A1 (en) *	2020-04-27	2023-07-06	Fred Hutchinson Cancer Center	Neutralizing monoclonal antibodies against covid19
CN115812077A (zh)	2020-05-08	2023-03-17	高山免疫科学股份有限公司	April和baff抑制性免疫调节蛋白及其使用方法
WO2022132887A1 (en) *	2020-12-15	2022-06-23	Board Of Regents, The University Of Texas System	Human monoclonal antibodies targeting the sars-cov-2 spike protein
WO2022236047A1 (en)	2021-05-07	2022-11-10	Viela Bio, Inc.	Use of an anti-cd19 antibody to treat myasthenia gravis
AU2022317215A1 (en)	2021-07-27	2024-02-29	Astrazeneca Ab	Treatment of lupus
CN117003872A (zh) *	2022-04-28	2023-11-07	北京天广实生物技术股份有限公司	含有突变轻链可变区骨架的单链抗体片段
WO2024018350A1 (en) *	2022-07-19	2024-01-25	Novartis Ag	Treatment of aiha with baff or baff receptor inhibitory antibodies

Family Cites Families (244)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en) *	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4714681A (en)	1981-07-01	1987-12-22	The Board Of Reagents, The University Of Texas System Cancer Center	Quadroma cells and trioma cells and methods for the production of same
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US4631211A (en)	1985-03-25	1986-12-23	Scripps Clinic & Research Foundation	Means for sequential solid phase organic synthesis and methods using the same
EP0216846B2 (en)	1985-04-01	1995-04-26	Celltech Limited	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4980286A (en)	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5576195A (en) *	1985-11-01	1996-11-19	Xoma Corporation	Vectors with pectate lyase signal sequence
EP0247091B1 (en)	1985-11-01	1993-09-29	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US4994560A (en)	1987-06-24	1991-02-19	The Dow Chemical Company	Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5489425A (en)	1987-06-24	1996-02-06	The Dow Chemical Company	Functionalized polyamine chelants
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
US5336603A (en)	1987-10-02	1994-08-09	Genentech, Inc.	CD4 adheson variants
GB8725529D0 (en)	1987-10-30	1987-12-02	Delta Biotechnology Ltd	Polypeptides
DE68921982D1 (de)	1988-06-14	1995-05-04	Cetus Oncology Corp	Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
ZA894792B (en)	1988-06-24	1991-04-24	Dow Chemical Co	Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates
ATE120457T1 (de)	1988-06-24	1995-04-15	Dow Chemical Co	Macrocyclische bifunktionelle chelatbildner, komplexe davon und ihre konjugierten antikörper.
US5756065A (en)	1988-06-24	1998-05-26	The Dow Chemical Company	Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
US5274119A (en)	1988-07-01	1993-12-28	The Dow Chemical Company	Vicinal diols
US4925648A (en)	1988-07-29	1990-05-15	Immunomedics, Inc.	Detection and treatment of infectious and inflammatory lesions
US5601819A (en)	1988-08-11	1997-02-11	The General Hospital Corporation	Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
EP1997891A1 (en)	1988-09-02	2008-12-03	Dyax Corporation	Generation and selection of recombinant varied binding proteins
KR900005995A (ko)	1988-10-31	1990-05-07	우메모또 요시마사	변형 인터류킨-2 및 그의 제조방법
US5342604A (en)	1988-10-31	1994-08-30	The Dow Chemical Company	Complexes possessing ortho ligating functionality
US5696239A (en)	1988-10-31	1997-12-09	The Dow Chemical Company	Conjugates possessing ortho ligating functionality and complexes thereof
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
EP0394827A1 (en)	1989-04-26	1990-10-31	F. Hoffmann-La Roche Ag	Chimaeric CD4-immunoglobulin polypeptides
US5766883A (en)	1989-04-29	1998-06-16	Delta Biotechnology Limited	Polypeptides
ZA902949B (en)	1989-05-05	1992-02-26	Res Dev Foundation	A novel antibody delivery system for biological response modifiers
US6291161B1 (en) *	1989-05-16	2001-09-18	Scripps Research Institute	Method for tapping the immunological repertiore
US5808003A (en)	1989-05-26	1998-09-15	Perimmune Holdings, Inc.	Polyaminocarboxylate chelators
CA2062795A1 (en)	1989-06-29	1990-12-30	Michael W. Fanger	Bispecific reagents for aids therapy
US6020145A (en) *	1989-06-30	2000-02-01	Bristol-Myers Squibb Company	Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5112946A (en)	1989-07-06	1992-05-12	Repligen Corporation	Modified pf4 compositions and methods of use
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
FR2650598B1 (fr)	1989-08-03	1994-06-03	Rhone Poulenc Sante	Derives de l'albumine a fonction therapeutique
US5073627A (en)	1989-08-22	1991-12-17	Immunex Corporation	Fusion proteins comprising GM-CSF and IL-3
US5436146A (en)	1989-09-07	1995-07-25	The Trustees Of Princeton University	Helper-free stocks of recombinant adeno-associated virus vectors
GB8923843D0 (en) *	1989-10-23	1989-12-13	Salutar Inc	Compounds
WO1991006570A1 (en)	1989-10-25	1991-05-16	The University Of Melbourne	HYBRID Fc RECEPTOR MOLECULES
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5780225A (en)	1990-01-12	1998-07-14	Stratagene	Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en)	1990-01-11	1991-08-05	Molecular Affinities Corporation	Production of antibodies using gene libraries
ATE356869T1 (de)	1990-01-12	2007-04-15	Amgen Fremont Inc	Bildung von xenogenen antikörpern
US5314995A (en)	1990-01-22	1994-05-24	Oncogen	Therapeutic interleukin-2-antibody based fusion proteins
ATE158615T1 (de)	1990-03-20	1997-10-15	Univ Columbia	Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
US5349053A (en)	1990-06-01	1994-09-20	Protein Design Labs, Inc.	Chimeric ligand/immunoglobulin molecules and their uses
US5635384A (en) *	1990-06-11	1997-06-03	Dowelanco	Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
DE69127627T2 (de)	1990-08-29	1998-02-19	Genpharm Int	Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
CA2092323A1 (en)	1990-10-01	1992-04-02	George Y. Wu	Targeting viruses and cells for selective internalization by cells
ES2129029T5 (es)	1990-10-05	2005-10-16	Celldex Therapeutics, Inc.	Inmunoestimulacion dirigida con reactivos biespecificos.
AU8727291A (en)	1990-10-29	1992-06-11	Cetus Oncology Corporation	Bispecific antibodies, method of production, and uses thereof
WO1992008495A1 (en)	1990-11-09	1992-05-29	Abbott Biotech, Inc.	Cytokine immunoconjugates
DE69129154T2 (de)	1990-12-03	1998-08-20	Genentech, Inc., South San Francisco, Calif.	Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
EP0517895B1 (en)	1990-12-14	1996-11-20	Cell Genesys, Inc.	Chimeric chains for receptor-associated signal transduction pathways
ES2149772T5 (es)	1991-03-29	2008-02-16	Genentech, Inc.	Receptores humanos pf4a y su utilizacion.
AU662148B2 (en)	1991-04-10	1995-08-24	Scripps Research Institute, The	Heterodimeric receptor libraries using phagemids
DE69214709T2 (de)	1991-04-26	1997-02-20	Surface Active Ltd	Neue Antikörper und Verfahren zu ihrer Verwendung
EP0584279B1 (en)	1991-05-14	2001-03-14	The University Of Connecticut	Targeted delivery of genes encoding immunogenic proteins
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
JPH06510278A (ja)	1991-06-05	1994-11-17	ユニバーシティオブコネチカット	分泌タンパク質をコードする遺伝子の標的への配達
CA2110799A1 (en)	1991-06-14	1992-12-23	Arnold H. Horwitz	Microbially-produced antibody fragments and their conjugates
IL99120A0 (en)	1991-08-07	1992-07-15	Yeda Res & Dev	Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
US5376546A (en) *	1991-11-04	1994-12-27	Xoma Corporation	Analogs of ribosome-inactivating proteins
PT1024191E (pt)	1991-12-02	2008-12-22	Medical Res Council	Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5428139A (en)	1991-12-10	1995-06-27	The Dow Chemical Company	Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
AU3434393A (en)	1992-01-17	1993-08-03	Regents Of The University Of Michigan, The	Targeted virus
US5622929A (en)	1992-01-23	1997-04-22	Bristol-Myers Squibb Company	Thioether conjugates
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ATE239506T1 (de)	1992-03-05	2003-05-15	Univ Texas	Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5447851B1 (en)	1992-04-02	1999-07-06	Univ Texas System Board Of	Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
AU3940293A (en)	1992-04-03	1993-11-08	Alexander T. YOUNG	Gene therapy using targeted viral vectors
ZA932522B (en)	1992-04-10	1993-12-20	Res Dev Foundation	Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
BR9305516A (pt)	1992-06-09	1995-03-01	Hoppe Ag	Sistema de trinco e fechadura
US5962301A (en) *	1992-06-12	1999-10-05	Massachusetts Institute Of Technology	Relatedness of human interleukin-1β convertase gene to a C. elegans cell death gene, inhibitory portions of these genes and uses therefor
US5505931A (en)	1993-03-04	1996-04-09	The Dow Chemical Company	Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
EP0749475A4 (en)	1992-08-26	1997-05-07	Harvard College	USE OF CYTOKINE IP-10 AS ANTI-TUMOR AGENT
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5605671A (en) *	1992-10-05	1997-02-25	The Regents Of The University Of Michigan	Radiolabeled neutrophil activating peptides for imaging
CA2146747C (en)	1992-10-09	2006-12-19	Brian A. Naughton	Liver reserve cells
US5869331A (en) *	1992-11-20	1999-02-09	University Of Medicine & Dentistry Of New Jersey	Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
US5589499A (en)	1992-11-25	1996-12-31	Weth; Gosbert	Dopaminergic agents for the treatment of cerebral and peripheral blood flow disorders
EP0905253A3 (en)	1992-12-03	2000-11-02	Genzyme Corporation	Adenoviral vector deleted of all E4-ORF except ORF6
US5441050A (en)	1992-12-18	1995-08-15	Neoprobe Corporation	Radiation responsive surgical instrument
WO1994020540A1 (es)	1993-03-02	1994-09-15	Universidad De Valladolid	PROTEINAS INACTIVADORAS DE RIBOSOMAS (RIPs) DE DOS CADENAS NO TOXICAS, PROCEDIMIENTO PARA SU PREPARACION Y APLICACIONES
AU7694594A (en)	1993-09-06	1995-03-27	Menarini Ricerche Sud S.P.A.	Ribosome inactivating proteins extracted from seeds of saponaria ocymoides and vaccaria pyramidata, their preparation and immunotoxins containing them
US5595721A (en) *	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
US5643575A (en) *	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
EP0733070A1 (en)	1993-12-08	1996-09-25	Genzyme Corporation	Process for generating specific antibodies
US5597709A (en)	1994-01-27	1997-01-28	Human Genome Sciences, Inc.	Human growth hormone splice variants hGHV-2(88) and hGHV-3(53)
ES2201097T3 (es)	1994-01-31	2004-03-16	Trustees Of Boston University	Bibliotecas de anticuerpos policlonales.
US5837458A (en)	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
US5834252A (en)	1995-04-18	1998-11-10	Glaxo Group Limited	End-complementary polymerase reaction
US5605793A (en) *	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US5817485A (en)	1994-03-08	1998-10-06	Human Genome Sciences, Inc.	Nucleic acids and cells for recombinant production of fibroblast growth factor-10
US5633147A (en)	1994-03-08	1997-05-27	Human Genome Sciences, Inc.	Transforming growth factor αH1
WO1995031468A1 (en)	1994-05-16	1995-11-23	Human Genome Sciences, Inc.	Macrophage migration inhibitory factor-3
US5516637A (en)	1994-06-10	1996-05-14	Dade International Inc.	Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5985660A (en)	1994-06-15	1999-11-16	Systemix, Inc.	Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
EP0770135A1 (en)	1994-07-29	1997-05-02	Smithkline Beecham Plc	Novel compounds
KR100507431B1 (ko)	1994-11-07	2005-12-21	휴먼 게놈 사이언시즈, 인코포레이티드	종양괴사인자-γ
EP1323346B1 (en)	1995-01-17	2006-06-28	The Brigham And Women's Hospital, Inc.	Receptor specific transepithelial transport of immunogens
US6030613A (en)	1995-01-17	2000-02-29	The Brigham And Women's Hospital, Inc.	Receptor specific transepithelial transport of therapeutics
AU2363695A (en)	1995-04-27	1996-11-18	Human Genome Sciences, Inc.	Human tumor necrosis factor receptors
EP1978033A3 (en)	1995-04-27	2008-12-24	Amgen Fremont Inc.	Human antibodies derived from immunized xenomice
CA2219486A1 (en)	1995-04-28	1996-10-31	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5874409A (en) *	1995-06-07	1999-02-23	La Jolla Pharmaceutical Company	APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
GB9601081D0 (en)	1995-10-06	1996-03-20	Cambridge Antibody Tech	Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja)	1996-01-24	1999-11-15	チッソ株式会社	アクリロキシプロピルシランの製造方法
US6635492B2 (en)	1996-01-25	2003-10-21	Bjs Company Ltd.	Heating specimen carriers
WO1997033904A1 (en)	1996-03-12	1997-09-18	Human Genome Sciences, Inc.	Death domain containing receptors
JP2001501453A (ja)	1996-03-14	2001-02-06	ヒューマンジノームサイエンシーズ，インコーポレイテッド	ヒト腫瘍壊死因子δおよびε
US6541224B2 (en) *	1996-03-14	2003-04-01	Human Genome Sciences, Inc.	Tumor necrosis factor delta polypeptides
AU5711196A (en)	1996-03-14	1997-10-01	Human Genome Sciences, Inc.	Apoptosis inducing molecule i
KR20030096450A (ko)	1996-03-22	2003-12-31	휴먼 게놈 사이언시즈, 인코포레이티드	고사 유도 분자 ⅱ
US5792850A (en)	1996-05-23	1998-08-11	Zymogenetics, Inc.	Hematopoietic cytokine receptor
US6300065B1 (en) *	1996-05-31	2001-10-09	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
EP0954531A1 (en)	1996-06-06	1999-11-10	Lajolla Pharmaceutical Company	aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
IT1286663B1 (it)	1996-06-27	1998-07-15	Ministero Uni Ricerca Scient E	Proteina capace di inibire l'attivita' ribosomiale,sua preparazione ed uso come immunoconiugato chimico o ricombinante e sequenza di cdna
EP2025682A3 (en)	1996-08-16	2009-06-17	Human Genome Sciences, Inc.	Human endokine alpha
DK0920505T3 (da)	1996-08-16	2008-09-08	Schering Corp	Pattedyrcelleoverfladeantigener og tilhörende reagenser
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
US20030175208A1 (en) *	1996-10-25	2003-09-18	Human Genome Sciences, Inc.	Neutrokine-alpha and neutrokine-alpha splice variant
US6812327B1 (en) *	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
US6689579B1 (en) *	1996-10-25	2004-02-10	Human Genome Sciences, Inc.	Polynucleotides encoding neutrokine-α
JP2001503263A (ja)	1996-10-25	2001-03-13	ヒューマンジノームサイエンシーズ，インコーポレイテッド	ニュートロカインα
US8212004B2 (en) *	1999-03-02	2012-07-03	Human Genome Sciences, Inc.	Neutrokine-alpha fusion proteins
US20020115112A1 (en) *	1999-02-23	2002-08-22	Human Genome Sciences, Inc.	Neutrokine-alpha and Neutrokine-alpha splice variant
JP4215172B2 (ja)	1996-12-03	2009-01-28	アムジェンフレモントインク．	複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
WO1998027114A2 (en)	1996-12-17	1998-06-25	Schering Corporation	Mammalian cell surface antigens; related reagents
CN1247567A (zh)	1997-01-14	2000-03-15	人体基因组科学有限公司	肿瘤坏死因子受体6α和6β
US6261801B1 (en)	1997-01-14	2001-07-17	Human Genome Sceineces, Inc.	Nucleic acids encoding tumor necrosis factor receptor 5
DE69837806T3 (de)	1997-01-28	2012-01-05	Human Genome Sciences, Inc.	"death-domain"-enthaltender rezeptor 4 (dr4), ein mitglied der tnf-rezeptor superfamilie, welcher an trail (apo-2l) bindet
US5969102A (en) *	1997-03-03	1999-10-19	St. Jude Children's Research Hospital	Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
EP0970213B1 (en)	1997-03-17	2007-01-24	Human Genome Sciences, Inc.	Death domain containing receptor 5
CA2232743A1 (en)	1997-04-02	1998-10-02	Smithkline Beecham Corporation	A tnf homologue, tl5
ATE200679T1 (de)	1997-04-14	2001-05-15	Micromet Ag	Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
AU7469998A (en)	1997-05-01	1998-11-24	Amgen, Inc.	Chimeric opg polypeptides
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
DK1798288T3 (da)	1997-05-07	2010-01-04	Schering Corp	Humane Toll-lignende receptorproteiner, relaterede reagenser og fremgangsmåder
JP2002511070A (ja)	1997-05-30	2002-04-09	ヒューマンジノームサイエンシーズ，インコーポレイテッド	ヒト腫瘍壊死因子受容体ｔｒ１０
WO1998055623A1 (en)	1997-06-06	1998-12-10	Tanox Pharma B.V.	Type-1 ribosome-inactivating protein
IL133315A0 (en)	1997-06-06	2001-04-30	Regeneron Pharma	Ntn-2 member of tnf ligand family
CA2292899A1 (en)	1997-06-06	1998-12-10	Regeneron Pharmaceuticals, Inc.	Ntn-2 member of tnf ligand family
CA2295991A1 (en)	1997-06-11	1998-12-17	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor tr9
US5948619A (en) *	1997-07-31	1999-09-07	Incyte Pharmaceuticals, Inc.	Human zygin-1
US6342220B1 (en) *	1997-08-25	2002-01-29	Genentech, Inc.	Agonist antibodies
AU9376498A (en)	1997-09-05	1999-03-22	University Of Washington	Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
US5795724A (en) *	1997-09-12	1998-08-18	Incyte Pharmaceuticals, Inc.	Human N-acetyl transferase
PL339740A1 (en)	1997-09-12	2001-01-02	Biogen	Kay - a novel immune system protein
EP1042343B1 (en)	1997-11-03	2008-01-23	Human Genome Sciences, Inc.	Vegi, an inhibitor of angiogenesis and tumor growth
US20010010925A1 (en) *	1997-11-17	2001-08-02	Steven R. Wiley	Methods of detecting target nucleic acids of tnf-delta
US20020055624A1 (en) *	1997-11-17	2002-05-09	Steven R. Wiley	Tnf-delta ligand and uses thereof
CA2310987A1 (en)	1997-11-26	1999-06-03	Eli Lilly And Company	Tnf ligand family gene
AU2093499A (en)	1997-12-30	1999-07-19	Chiron Corporation	Members of tnf and tnfr families
US6297367B1 (en)	1997-12-30	2001-10-02	Chiron Corporation	Polynucleotide encoding TNFL1
AU2212299A (en)	1998-01-05	1999-07-26	Genentech Inc.	Compositions and methods for the treatment of tumor
WO1999046295A1 (en)	1998-03-12	1999-09-16	Shanghai Second Medical University	A gene homologous to the drosophila b(2)gen gene and putative yeast 26.5kd protein ypr015c
ATE490980T1 (de)	1998-03-19	2010-12-15	Human Genome Sciences	Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
TR199903138T1 (xx)	1998-04-20	2000-11-21	Lss Life Support Systems Ag	H�za kar�� koruyucu elbise.
ATE365800T1 (de)	1998-05-15	2007-07-15	Genentech Inc	Therapeutische verwendungen von il-17 homologe polypeptide
AU1467000A (en)	1998-11-04	2000-05-22	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en) *	1998-12-23	1999-02-17	Glaxo Group Ltd	Novel ligand
US6297637B1 (en) *	1998-12-29	2001-10-02	Siemens Aktiengesellschaft	High-frequency receiver, particularly for a nuclear magnetic resonance apparatus
ES2338661T3 (es)	1999-01-07	2010-05-11	Zymogenetics, Inc.	Usos terapeuticos de receptores solubles br43x2.
US20030095967A1 (en) *	1999-01-25	2003-05-22	Mackay Fabienne	BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20050100548A1 (en) *	2001-07-24	2005-05-12	Biogen Idec Ma Inc.	BAFF, inhibitors thereof and their use in the modulation of B-cell response
AU762839B2 (en)	1999-01-25	2003-07-03	Apoxis Sa	Baff, related blocking agents and their use in the stimulation and inhibition of B-cells and immunoglobulins in immune responses
US6475986B1 (en)	1999-02-02	2002-11-05	Research Development Foundation	Uses of THANK, a TNF homologue that activates apoptosis
WO2000047740A2 (en)	1999-02-12	2000-08-17	Amgen Inc.	Tnf-related proteins
CA2363112A1 (en)	1999-02-23	2000-08-31	Craig A. Rosen	Neutrokine-alpha and neutrokine-alpha splice variant
AU3633000A (en)	1999-03-26	2000-10-16	Human Genome Sciences, Inc.	Neutrokine-alpha binding proteins and methods based thereon
US20030022233A1 (en)	1999-04-30	2003-01-30	Raymond G. Goodwin	Methods of use of the taci/taci-l interaction
AU4986700A (en)	1999-05-06	2000-11-21	National Jewish Medical And Research Center	Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
CA2382185A1 (en)	1999-06-11	2000-12-21	Human Genome Sciences, Inc.	48 human secreted proteins
BR0013391A (pt) *	1999-08-17	2002-07-09	Biogen Inc	Uso do receptor baff (bcma) como um agente imunoregulador
UA74798C2 (uk)	1999-10-06	2006-02-15	Байоджен Айдек Ма Інк.	Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2492049A1 (en)	1999-12-01	2001-06-07	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001058949A2 (en) *	2000-02-11	2001-08-16	Biogen, Inc.	Heterologous polypeptide of the tnf family
DE60028830T2 (de)	2000-02-16	2007-01-18	Genentech, Inc., South San Francisco	Anti-april antikörper und hybridomazellen
AU5392001A (en)	2000-04-27	2001-11-07	Biogen Inc	Taci as an anti-tumor agent
JP2003533218A (ja) *	2000-05-12	2003-11-11	アムジエン・インコーポレーテツド	Ａｐｒｉｌ／ｇ７０、ｂｃｍａ、ｂｌｙｓ／ａｇｐ−３及びｔａｃｉに関する物質の組成物及び使用方法
AU2001282856A1 (en)	2000-06-15	2001-12-24	Human Genome Sciences, Inc.	Human tumor necrosis factor delta and epsilon
US7879328B2 (en)	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002002641A1 (en) *	2000-06-16	2002-01-10	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to blys
US7220840B2 (en) *	2000-06-16	2007-05-22	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator protein
AU2001268363B2 (en) *	2000-06-20	2006-08-17	Biogen Idec Inc.	Treatment of B cell associated diseases
EP1309718A4 (en)	2000-08-15	2004-08-25	Human Genome Sciences Inc	NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT
JP2004532604A (ja) *	2000-08-18	2004-10-28	ダイアックスコーポレーション	Ｂリンパ球刺激因子タンパク質（ＢＬｙＳ）のための結合性ポリペプチド
AU2001288301A1 (en) *	2000-08-18	2002-03-04	Human Genome Sciences, Inc.	Binding polypeptides and methods based thereon
UA83458C2 (uk)	2000-09-18	2008-07-25	Байоджен Айдек Ма Інк.	Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
AU2002230659A1 (en)	2000-11-07	2002-05-21	Zymogenetics Inc.	Human tumor necrosis factor receptor
US20030012783A1 (en)	2001-02-20	2003-01-16	Wayne Kindsvogel	Antibodies that bind both BCMA and TACI
CZ304592B6 (cs) *	2001-05-11	2014-07-23	Amgen, Inc.	Molekula s aminokyselinovou sekvencí vázající TALL-1, DNA, expresní vektor a hostitelská buňka, léčení autoimunitních onemocnění zprostředkovaných B buňkami
NZ529638A (en)	2001-05-24	2007-08-31	Zymogenetics Inc	Taci-immunoglobulin fusion proteins
AR035119A1 (es) *	2001-08-16	2004-04-14	Lilly Co Eli	Anticuerpos humanos antagonistas anti-htnfsf13b
JP4002082B2 (ja) *	2001-09-14	2007-10-31	古河電気工業株式会社	光ファイバ母材およびその製造方法
US7521053B2 (en)	2001-10-11	2009-04-21	Amgen Inc.	Angiopoietin-2 specific binding agents
AU2002351495A1 (en)	2001-10-17	2003-04-28	Human Genome Sciences, Inc.	Neutrokine-alpha and neutrokine-alpha splice variant
EP1511511A4 (en)	2001-11-06	2006-03-29	Lilly Co Eli	USE OF IL-19, IL-22 AND IL-24 FOR THE TREATMENT OF HEMATOPOIETIC DISORDERS
AU2002364954A1 (en)	2001-11-16	2003-07-15	Human Genome Sciences, Inc.	ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
US20020150579A1 (en) *	2002-01-10	2002-10-17	Kimberly Robert P.	B lymphocyte stimulator (BLyS) as a marker in management of systemic lupus erythematosus
WO2003072713A2 (en) *	2002-02-21	2003-09-04	Biogen Idec Ma Inc.	Use of bcma as an immunoregulatory agent
WO2004058309A1 (en)	2002-12-23	2004-07-15	Human Genome Sciences, Inc.	Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
WO2004074511A1 (en)	2003-02-21	2004-09-02	Garvan Institute Of Medical Research	Diagnosis and treatment of baff-mediated autoimmune diseases and cancer
CA2526402A1 (en)	2003-06-05	2005-01-20	Genentech, Inc.	Blys antagonists and uses thereof
US20050163775A1 (en) *	2003-06-05	2005-07-28	Genentech, Inc.	Combination therapy for B cell disorders
WO2005042009A1 (en)	2003-10-20	2005-05-12	Biogen Idec Ma Inc.	Therapeutic regimens for baff antagonists
DE10355251A1 (de) *	2003-11-26	2005-06-23	Merck Patent Gmbh	Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
WO2006081516A2 (en) *	2005-01-28	2006-08-03	Biogen Idec Ma Inc.	USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS
WO2006083961A2 (en) *	2005-02-01	2006-08-10	Research Development Foundation	Blys fusion proteins for targeting blys receptor and methods for treatment of b-cell proliferative disorders
WO2007014390A2 (en) *	2005-07-28	2007-02-01	Biogen Idec Ma Inc.	Methods of targeting baff
NZ597082A (en) *	2005-10-13	2013-11-29	Human Genome Sciences Inc	Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
US9168286B2 (en) *	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007062090A2 (en) *	2005-11-23	2007-05-31	Genentech, Inc.	Methods and compositions related to b cell assays
US8211649B2 (en) *	2006-03-31	2012-07-03	Human Genome Sciences, Inc.	Methods of diagnosing and prognosing hodgkin's lymphoma
DK2139517T3 (da) *	2007-03-27	2013-08-26	Zymogenetics Inc	Kombination af blys inhibering og mycophenolat-mofetil til behandling af autoimmunsygdomme
EP2283355A2 (en)	2008-04-25	2011-02-16	Zymogenetics, Inc.	Levels of bcma protein expression on b cells and use in diagnostic methods
EP2396035A4 (en) *	2009-02-12	2012-09-12	Human Genome Sciences Inc	USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
EP2582392A4 (en)	2010-06-18	2015-02-18	Human Genome Sciences Inc	USE OF ANTAGONISTS OF A LYMPHOCYTE B STIMULATING PROTEIN FOR THE TREATMENT OF ASTHMA AND OTHER ALLERGIC AND INFLAMMATORY DISEASES OF THE RESPIRATORY SYSTEM

2001
- 2001-06-15 WO PCT/US2001/019110 patent/WO2002002641A1/en active IP Right Grant
- 2001-06-15 KR KR1020127008774A patent/KR20120053525A/ko not_active Application Discontinuation
- 2001-06-15 MX MXPA02012434A patent/MXPA02012434A/es active IP Right Grant
- 2001-06-15 CA CA2407910A patent/CA2407910C/en not_active Expired - Lifetime
- 2001-06-15 EP EP10185178.0A patent/EP2275449B1/en not_active Expired - Lifetime
- 2001-06-15 KR KR1020067011863A patent/KR20060088905A/ko not_active Application Discontinuation
- 2001-06-15 DE DE60143798T patent/DE60143798D1/de not_active Expired - Lifetime
- 2001-06-15 EP EP10185182A patent/EP2281842A1/en not_active Ceased
- 2001-06-15 PT PT101851780T patent/PT2275449T/pt unknown
- 2001-06-15 AU AU6842701A patent/AU6842701A/xx active Pending
- 2001-06-15 ES ES10185185.5T patent/ES2609583T3/es not_active Expired - Lifetime
- 2001-06-15 EP EP10185185.5A patent/EP2281843B1/en not_active Expired - Lifetime
- 2001-06-15 PT PT101851855T patent/PT2281843T/pt unknown
- 2001-06-15 AU AU2001268427A patent/AU2001268427B2/en active Active
- 2001-06-15 KR KR1020107026974A patent/KR101287395B1/ko not_active Expired - Lifetime
- 2001-06-15 EP EP01946365A patent/EP1294769B1/en not_active Expired - Lifetime
- 2001-06-15 ES ES10185178.0T patent/ES2609016T3/es not_active Expired - Lifetime
- 2001-06-15 ES ES01946365T patent/ES2358885T3/es not_active Expired - Lifetime
- 2001-06-15 DK DK01946365.2T patent/DK1294769T3/da active
- 2001-06-15 CN CNB01811296XA patent/CN1279055C/zh not_active Expired - Lifetime
- 2001-06-15 KR KR1020027017188A patent/KR101155294B1/ko active Protection Beyond IP Right Term
- 2001-06-15 NZ NZ522700A patent/NZ522700A/en not_active IP Right Cessation
- 2001-06-15 US US09/880,748 patent/US7138501B2/en not_active Expired - Lifetime
- 2001-06-15 JP JP2002507892A patent/JP4902087B2/ja not_active Expired - Lifetime
- 2001-06-15 AT AT01946365T patent/ATE494304T1/de active
2003
- 2003-06-03 HK HK03103931.3A patent/HK1051697A1/xx not_active IP Right Cessation
2005
- 2005-11-04 US US11/266,444 patent/US7605236B2/en not_active Expired - Lifetime
2008
- 2008-10-02 JP JP2008257439A patent/JP4902618B2/ja not_active Expired - Lifetime
2009
- 2009-03-09 AU AU2009200977A patent/AU2009200977B2/en not_active Expired
- 2009-09-02 US US12/552,915 patent/US8101181B2/en not_active Expired - Fee Related
2011
- 2011-04-04 CY CY20111100348T patent/CY1112793T1/el unknown
2012
- 2012-01-04 FR FR12C0001C patent/FR12C0001I2/fr active Active
- 2012-01-04 LU LU91926C patent/LU91926I2/fr unknown
- 2012-01-10 CY CY2012003C patent/CY2012003I2/el unknown
- 2012-01-12 BE BE2012C005C patent/BE2012C005I2/fr unknown
- 2012-01-23 US US13/356,314 patent/US9187548B2/en not_active Expired - Fee Related
2016
- 2016-12-13 CY CY20161101283T patent/CY1118317T1/el unknown
- 2016-12-19 CY CY20161101319T patent/CY1118363T1/el unknown

Also Published As

Publication number	Publication date
EP2281843B1 (en)	2016-10-12
HK1051697A1 (en)	2003-08-15
ES2358885T3 (es)	2011-05-16
CY1112793T1 (el)	2016-02-10
AU6842701A (en)	2002-01-14
BE2012C005I2 (el)	2020-08-20
FR12C0001I1 (el)	2012-02-24
EP2275449A1 (en)	2011-01-19
CY1118317T1 (el)	2017-06-28
KR20100133025A (ko)	2010-12-20
KR101155294B1 (ko)	2013-03-07
CA2407910C (en)	2013-03-12
US20120121606A1 (en)	2012-05-17
US9187548B2 (en)	2015-11-17
KR20120053525A (ko)	2012-05-25
KR20030038557A (ko)	2003-05-16
US7138501B2 (en)	2006-11-21
KR20060088905A (ko)	2006-08-07
CN1279055C (zh)	2006-10-11
EP2281842A1 (en)	2011-02-09
CA2407910A1 (en)	2002-01-10
CY1118363T1 (el)	2017-06-28
JP4902087B2 (ja)	2012-03-21
LU91926I2 (fr)	2012-03-05
WO2002002641A1 (en)	2002-01-10
US20100003259A1 (en)	2010-01-07
EP1294769A1 (en)	2003-03-26
PT2275449T (pt)	2016-12-27
JP2004509615A (ja)	2004-04-02
EP2275449B1 (en)	2016-09-28
EP1294769B1 (en)	2011-01-05
FR12C0001I2 (fr)	2014-05-16
DE60143798D1 (de)	2011-02-17
DK1294769T3 (da)	2011-04-26
US8101181B2 (en)	2012-01-24
PT2281843T (pt)	2017-01-02
US20030059937A1 (en)	2003-03-27
ES2609583T3 (es)	2017-04-21
ES2609016T3 (es)	2017-04-18
JP4902618B2 (ja)	2012-03-21
JP2009095346A (ja)	2009-05-07
KR101287395B1 (ko)	2014-11-04
US7605236B2 (en)	2009-10-20
AU2009200977B2 (en)	2012-11-15
CN1492878A (zh)	2004-04-28
ATE494304T1 (de)	2011-01-15
US20060062789A1 (en)	2006-03-23
NZ522700A (en)	2006-02-24
AU2001268427B2 (en)	2007-03-29
EP1294769A4 (en)	2004-07-28
CY2012003I2 (el)	2020-05-29
EP2281843A1 (en)	2011-02-09
MXPA02012434A (es)	2004-09-06
AU2009200977A1 (en)	2009-04-02

Publication	Publication Date	Title
CY2012003I1 (el)	2016-12-14	Αντισωματα που συνδεονται ανοσοειδικως προς blys
AU2002364954A8 (en)	2003-07-15	Antibodies that immunospecifically bind to blys
EE200300509A (et)	2004-08-16	Antikehad VLA-1 vastu
EP1465925A4 (en)	2006-02-08	"ANTIBODIES THAT IMMUNE SPECIFICALLY TO TRAIL RECEPTORS"
HK1075470A1 (en)	2005-12-16	Antibodies that immunospecifically bind to trail receptors
AR027976A1 (es)	2003-04-23	Anticuerpos humanos para cd154
NO20032585D0 (no)	2003-06-06	ABCA-1 forhöyende forbindelser
NO20023266D0 (no)	2002-07-05	Antistoffer mot humant IL-1
NO20026063L (no)	2003-02-27	Antistoffer mot human MCP-1
DK1409016T3 (da)	2010-06-21	Antistoffer mod OPGL
NO20042388L (no)	2004-08-09	Antistoff mot CD40
DE60134148D1 (de)	2008-07-03	Antikörper gegen il-1 beta
IS6779A (is)	2003-04-11	Mannlíkt mótefni gegn LT-beta-R
ATE517855T1 (de)	2011-08-15	Antikörper gegen chemotaktische monozytenproteine
IS6686A (is)	2003-01-16	Hýdrógel-drifið lyfjaskömmtunarform
IS2932B (is)	2015-12-15	Fúlvestrant samsetning
NO20025371D0 (no)	2002-11-08	Forbedringer til fluorescense polymer-QTL tilnirming til biodetektering
EP1572874A3 (en)	2005-10-20	Antibodies that immunospecifically bind to trail receptors
DE60108136D1 (de)	2005-02-03	Benzinzusammensetzung
DK1524266T3 (da)	2007-06-25	Farmaceutisk sammensætning
DE60100269D1 (de)	2003-06-18	Scheinwerfer
AU2003234706A8 (en)	2003-11-03	Antibodies that specifically bind to tl5
AU2003218456A8 (en)	2003-10-20	Antibodies that specifically bind to gmad
EE200300569A (et)	2004-04-15	CD44v6-spetsiifilised antikehad
DE60116858D1 (de)	2006-04-13	Zusammensetzung